Cargando…

Targeting HER2 in Nuclear Medicine for Imaging and Therapy

Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massicano, Adriana V. F., Marquez-Nostra, Bernadette V., Lapi, Suzanne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784567/ https://www.ncbi.nlm.nih.gov/pubmed/29357745 http://dx.doi.org/10.1177/1536012117745386

Ejemplares similares

Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer
por: Li, Ziqi, et al.
Publicado: (2022)

[(89)Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
por: Lu, Yun, et al.
Publicado: (2021)

[(89)Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
por: Massicano, Adriana V. F., et al.
Publicado: (2023)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
por: Miladinova, Daniela
Publicado: (2023)

Radiolabeled Cationic Peptides for Targeted Imaging of Infection
por: Aweda, Tolulope A., et al.
Publicado: (2019)

Peptide Based Imaging Agents for HER2 Imaging in Oncology
por: Ducharme, Maxwell, et al.
Publicado: (2020)

(89)Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model
por: Stone, Logan D., et al.
Publicado: (2022)

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
por: Marquez-Nostra, Bernadette V., et al.
Publicado: (2017)

Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
por: Ducharme, Maxwell, et al.
Publicado: (2022)

Essential Metal Uptake in Gram-negative Bacteria: X-ray Fluorescence, Radioisotopes, and Cell Fractionation
por: Radka, Christopher D., et al.
Publicado: (2018)

PET Imaging in Animal Models of Alzheimer’s Disease
por: Chen, Baosheng, et al.
Publicado: (2022)

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
por: Ikotun, Oluwatayo F., et al.
Publicado: (2013)

Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
por: Fang, Hanyi, et al.
Publicado: (2021)

Positron emission tomography imaging with (89)Zr-labeled anti-CD8 cys-diabody reveals CD8(+) cell infiltration during oncolytic virus therapy in a glioma murine model
por: Kasten, Benjamin B., et al.
Publicado: (2021)

Author Correction: Positron emission tomography imaging with (89)Zr-labeled anti-CD8 cys-diabody reveals CD8(+) cell infiltration during oncolytic virus therapy in a glioma murine model
por: Kasten, Benjamin B., et al.
Publicado: (2021)

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer
por: Li, Ziqi, et al.
Publicado: (2023)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
por: Guan, Siao-Syun, et al.
Publicado: (2018)

Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents
por: Winuprasith, Thunnalin, et al.
Publicado: (2023)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Nuclear medicine imaging and therapy of neuroendocrine tumours
por: Gotthardt, Martin, et al.
Publicado: (2006)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Exciting Opportunities in Nuclear Medicine Imaging and Therapy
por: Lapa, Constantin
Publicado: (2019)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer
por: Song, Patrick N., et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

Positron Emission Tomography Imaging of Macrophages in Cancer
por: Parker, Candace C., et al.
Publicado: (2021)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Imaging in nuclear medicine
por: Giussani, Augusto, et al.
Publicado: (2013)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Molecular mechanisms of resistance to HER2-targeted therapy
por: Esteva, FJ
Publicado: (2009)

Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm
por: Cobain, Erin F., et al.
Publicado: (2022)

Advances in Targeting HER3 as an Anticancer Therapy
por: Jiang, Ning, et al.
Publicado: (2012)

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
por: Lheureux, S., et al.
Publicado: (2017)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Therapy and Nuclear Medicine
por: O’Doherty, M J
Publicado: (1998)

Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission
por: Shipunova, Victoria O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fffk7s0hj6o54cttlulcn27ua8